Gian Life Care Ltd

Gian Life Care Ltd has entered into a Hospital Lab Management Services Agreement with M/s. Brahma Hospital (HUF). The agreement is expected to enhance the revenue of Gian Life Care Ltd by approximately INR 1 Crore annually and increase its net profit by approx INR 18-20 Lakhs annually. The agreement will allow Gian Life Care Ltd to strengthen its market position in providing diagnostic and related healthcare services in Roorkee, Uttarakhand. The initial term of the agreement is 5 years, commencing from March 01, 2026.

Gian Life Care Ltd has announced its quarterly results for the period ended December 31, 2025. The company reported an unaudited standalone financial result with a cash balance of approximately ¥ 743.78 lakhs. However, there are statutory dues amounting to ¥ 426.66 lakhs and an outstanding bank loan classified as Non-Performing Asset (NPA) amounting to ¥ 359.78 lakhs that remain unpaid. The company could not provide sufficient and appropriate audit evidence for the rationale of retaining such a high cash balance without settling the aforesaid dues, and physical verification of cash as at the reporting date could not be carried out. The review report was conducted by MSNT & ASSOCIATES LLP.

Gian Life Care Ltd. announced its unaudited standalone and consolidated financial results for the quarter/period ended December 31, 2025. The company's board of directors approved the results during their meeting on February 14, 2026. The highlights of the meeting include the approval of financial results, the inability of the company to provide sufficient and appropriate audit evidence for the high cash balance, and the existence of unpaid statutory dues and an outstanding bank loan classified as Non-Performing Asset (NPA). The company's head office is located in Noida and the branch office in Navi Mumbai.

Gian Life Care Ltd has announced that its Board of Directors will meet on February 14, 2026, to consider and approve the Unaudited Standalone and Consolidated Financial Results for the quarter ended on December 31, 2025. The meeting will take place in Kanpur. The trading window for dealing in shares of the company has been closed from January 1, 2026, for all Directors, KMP's, Designated Employees, and Connected Persons of the Company as defined in the Code. The window will remain closed until 48 hours after the information is made public.

Gian Life Care Ltd. has approved the unaudited standalone and consolidated financial results for the quarter and half year ended 30th September 2025. The company reported a revenue from operations of INR 152.70 lakhs for the quarter and INR 663.10 lakhs for the half year. The total revenue for the quarter is INR 2,453 lakhs and INR 9,526.40 lakhs for the half year. The company's total expenses for the quarter are INR 2,301.20 lakhs and INR 7,080.30 lakhs for the half year. The profit before exceptional items and tax for the quarter is INR 151.80 lakhs and INR 245.10 lakhs for the half year. The company has a cash balance of INR 743.78 lakhs as of the reporting date, while statutory dues amounting to INR 426.66 lakhs and an outstanding bank loan classified as Non-Performing Asset (NPA) amounting to INR 359.78 lakhs remain unpaid. The auditors were unable to conclude on the existence and appropriateness of the cash balance due to insufficient audit evidence and the inability to carry out physical verification of cash.

Gian Life Care Ltd has announced its unaudited standalone and consolidated financial results for the quarter/half year ended September 30, 2025. The company reported a revenue from operations of Rs. 663.10 lakhs. The total revenue stands at Rs. 2453 lakhs. However, the company has a cash balance of approximately Rs. 743.78 lakhs, while statutory dues amounting to Rs. 426.66 lakhs and an outstanding bank loan classified as Non-Performing Asset (NPA) amounting to Rs. 359.78 lakhs remain unpaid. The company could not provide sufficient and appropriate audit evidence explaining the rationale for retention of such a high cash balance without settlement of the aforesaid dues, which raises concerns about the existence and appropriateness of the cash balance and the related disclosures in the financial results.

Gian Life Care Ltd has informed the BSE that the meeting of the Board of Directors, originally scheduled for January 24, 2026, has been rescheduled to January 28, 2026. The primary agenda of the meeting remains unchanged, which includes the consideration and approval of the unaudited standalone and consolidated financial results for the quarter or period ended September 30, 2025. The trading window for dealing in shares of the company has been closed for Directors, KMP's, Designated Employees, and Connected Persons from October 1, 2025, and will remain closed till 48 hours after the information is made public.

Gian Life Care Ltd has informed the BSE that its Board of Directors will meet on January 24, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter ended September 30, 2025. The meeting, originally scheduled for February 21, 2026, has been rescheduled. The trading window for dealing in shares of the company has been closed for Directors, KMP’s, Designated Employees and Connected Persons from October 1, 2025, and will remain closed till 48 hours after the information is made public.

Gian Life Care Ltd has announced that its Board of Directors will meet on 21st February, 2026 to consider and approve the Unaudited Standalone and Consolidated Financial Results for the quarters ended 30th September, 2025 and 31st December, 2025. The meeting will take place in Kanpur. The trading window for dealing in shares of the company has been closed from 1st October, 2025 for all Directors, KMP’s, Designated Employees and Connected Persons of the Company as defined in the Code, and will remain closed till 48 hours after the information is made public.

Gian Life Care Ltd. held its 7th Annual General Meeting on September 30, 2025, where the audited financial statements for the year ended March 31, 2025, were approved. The Reports of the Board of Directors and Auditors were also adopted. Mr. Shivam Mamgain, who retired by rotation, offered himself for re-appointment and was approved as a Director of the Company. The meeting was conducted with the requisite quorum and facilitated remote e-voting for shareholders. The Chairman provided an overview of the Company's business and financial performance and addressed shareholder queries.